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A twelve year old girl of Pakistani origin first presented at
the age of nine with weakness, lethargy, fever, and was
diagnosed as SLE with progressive multisystem involve-
ment with LV dysfunction, vasculitic skin lesions, hepati-
tis, hemiplegia and nephritis.
She was treated initially with Cyclophosphamide and
intravenous steroids, and thereafter maintained on Meth-
otrexate. She was also treated with Azathioprine and Myc-
ophenolate mofetil as single agents for some time as she
became non compliant with Methotrexate.
Three years into diagnosis she had symptoms of increas-
ing tiredness, breathlessness and tachycardia. An echocar-
diogram confirmed ventricular dilatation suggesting
myocardial involvement. She was recommenced on
Cyclophosphamide with Methyprednisolone, and was
also commenced on Frusemide and Enalapril which initi-
ated control of her cardiac function. Her ejection fraction
improved from 30% to 52%. Subsequently, after 6
months of Cyclophosphamide, Rituximab was tried as
sole agent which is currently holding her lupus and myo-
cardial changes in control for over 20 months. She has
had 3 cycles of Rituximab, each given at 1 gram/kg,
divided in two doses two weeks apart. Her latest ejection
fraction is 45%.
There is very limited published evidence for Rituximab for
cardiac involvement of SLE in children. Thus we would
recommend that Rituximab be considered in this rare but
potentially debilitating presentation of SLE for control as
well as to limit the use of large doses of cytotoxic medica-
tions.
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